The award recognises the results achieved by Lux's pioneering research and development and the company's contribution to enhancing the reputation of the Scottish biotechnology industry
As a specialist developer of detection technologies based on advanced imaging techniques, the company currently markets and develops a range of products including laboratory and diagnostic reagents, chemicals, water contamination monitors, and calibration devices.
Artin Moussavi (chief executive and director) and Patrick Hickey (director and founder) of Lux were present at the award ceremony, which was part of the Scottish Council for Development and Industry (SCDI) gala dinner on Friday 17 November.
Moussavi was presented with the award by Douglas Alexander MP, secretary of state for Scotland.
Declan Doogan, Pfizer senior vice president of clinical research and development, said: "It gives me great pleasure to award Lux Biotechnology with the Pfizer award for innovation in life sciences 2006.
"Such revolutionary technologies deserve recognition, and Lux's products are undoubtedly an important advancement in the world of life sciences.
"Their luminescence and fluorescence products both have their own specific qualities and will be valuable research tools in science".
On receiving the award Artin Moussavi said, "I am delighted that Lux Biotechnology has been nominated and awarded the Pfizer award for innovation in life sciences 2006".
"As a company focussed on developing novel products and technologies, the recognition of Lux's expertise and efforts is particularly gratifying to us.
"I'm sure the award will help to generate more awareness of our activities and abilities as we continue to grow and develop."
